Brian E. Krumm

Brian E. Krumm

Auto-generated profile, based on publicly available information

Brian E. Krumm

Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
ROReid H. J. Olsen
Reid H. J. Olsen
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
JEJustin G. English
Justin G. English
AGAlexis M. Glaudin
Alexis M. Glaudin
BKBrian E. Krumm
Brian E. Krumm
RSRyan T. Strachan
Ryan T. Strachan

17 November 2021 in Nature
Verified
Journal Article
Closed access
PDF file
CCCan Cao
Can Cao
HKHye Jin Kang
Hye Jin Kang
ISIsha Singh
Isha Singh
HCHe Chen
He Chen
CZChengwei Zhang
Chengwei Zhang
BRBryan L. Roth
Bryan L. Roth

2 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTao Che/Washington Che
Tao Che/Washington Che
JEJustin English
Justin English
BKBrian E. Krumm
Brian E. Krumm
KKKuglae Kim
Kuglae Kim
EPEls Pardon
Els Pardon
BRBryan L. Roth
Bryan L. Roth
Recent studies show that GPCRs rapidly interconvert between multiple states although our ability to interrogate, monitor and visualize them is limited by a relative lack of suitable tools. We previously reported two nanobodies (Nb39 and Nb6) that stabilize distinct ligand- and efficacy-delimited conformations of the kappa opioid receptor. Here, we demonstrate via X-ray crystallography a nanobody-targeted allosteric binding site by which Nb6 stabilizes a ligand-dependent inactive state. As Nb39 stabilizes an active-like state, we show how these two state-dependent nanobodies can provide real-time reporting of ligand stabilized states in cells in situ. Significantly, we demonstrate that chimeric GPCRs can be created with engineered nanobody binding sites to report ligand-stabilized states. Our results provide both insights regarding potential mechanisms for allosterically modulating KOR with nanobodies and a tool for reporting the real-time, in situ dynamic range of GPCR activity.

9 March 2021 in Cell Research
Verified
Journal Article
Open access
PDF file
YZYouwen Zhuang
Youwen Zhuang
BKBrian Krumm
Brian Krumm
HZHuibing Zhang
Huibing Zhang
XZX. Edward Zhou
X. Edward Zhou
YWYue Wang
Yue Wang
HXH. Eric Xu
H. Eric Xu

10 April 2024 in Nature
Verified
Journal Article
Closed access
PDF file
YKYoojoong Kim
Yoojoong Kim
RGRyan H. Gumpper
Ryan H. Gumpper
YLYongfeng Liu
Yongfeng Liu
DKD. Dewran Kocak
D. Dewran Kocak
YXYan Xiong
Yan Xiong
BRBryan L. Roth
Bryan L. Roth

11 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ADAmal El Daibani
Amal El Daibani
JPJoseph M. Paggi
Joseph M. Paggi
KKKuglae Kim
Kuglae Kim
YLYianni D. Laloudakis
Yianni D. Laloudakis
PPPetr Popov
Petr Popov
TCTao Che/Washington Che
Tao Che/Washington Che
The κ-opioid receptor (KOR) has emerged as an attractive drug target for pain management without addiction, and biased signaling through particular pathways of KOR may be key to maintaining this benefit while minimizing side-effect liabilities. As for most G protein-coupled receptors (GPCRs), however, the molecular mechanisms of ligand-specific signaling at KOR have remained unclear. To better understand the molecular determinants of KOR signaling bias, we apply structure determination, atomic-level molecular dynamics (MD) simulations, and functional assays. We determine a crystal structure of KOR bound to the G protein-biased agonist nalfurafine, the first approved KOR-targeting drug. We also identify an arrestin-biased KOR agonist, WMS-X600. Using MD simulations of KOR bound to nalfurafine, WMS-X600, and a balanced agonist U50,488, we identify three active-state receptor conformations, including one that appears to favor arrestin signaling over G protein signaling and another that appears to favor G protein signaling over arrestin signaling. These results, combined with mutagenesis validation, provide a molecular explanation of how agonists achieve biased signaling at KOR.